Kalaris Therapeutics Inc. (KLRS) – What Are Brokerages Thinking About This Stock?

Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS) have earned a consensus rating of “Moderate Buy” from the seven ratings firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $18.75.

A number of analysts have recently commented on KLRS shares. Wall Street Zen lowered Kalaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, September 13th. Weiss Ratings raised Kalaris Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 24th.

Kalaris Therapeutics Stock Down 4.5%

NASDAQ KLRS opened at $1.91 on Tuesday. Kalaris Therapeutics has a twelve month low of $1.87 and a twelve month high of $11.88. The company has a market cap of $45.48 million, a price-to-earnings ratio of -0.95 and a beta of 0.42. The business’s fifty day moving average is $3.31 and its 200 day moving average is $4.32.

Kalaris Therapeutics (NASDAQ:KLRS) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.02. On average, research analysts anticipate that Kalaris Therapeutics will post -1.99 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kalaris Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in KLRS. ADAR1 Capital Management LLC bought a new position in shares of Kalaris Therapeutics during the second quarter valued at $407,000. Simplify Asset Management Inc. increased its holdings in Kalaris Therapeutics by 335.5% in the first quarter. Simplify Asset Management Inc. now owns 87,426 shares of the company’s stock valued at $504,000 after purchasing an additional 67,352 shares during the period. BlackRock Inc. acquired a new stake in Kalaris Therapeutics in the second quarter valued at $222,000. Pale Fire Capital SE acquired a new stake in Kalaris Therapeutics in the second quarter valued at $161,000. Finally, Stonepine Capital Management LLC bought a new position in Kalaris Therapeutics during the 2nd quarter worth $122,597. 66.05% of the stock is currently owned by institutional investors and hedge funds.

About Kalaris Therapeutics

Kalaris Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for retinal vascular diseases. The company’s work is aimed at addressing conditions in which abnormal blood-vessel growth or leakage can impair vision.

Kalaris Therapeutics’ lead investigational product is KAL-001, an ophthalmic biologic being developed for retinal diseases, including conditions such as diabetic macular edema and neovascular age-related macular degeneration. The company’s pipeline remains under clinical development, and its products have not been established as safe or effective for commercial use.

The company is headquartered in the United States and is focused primarily on advancing its retinal-disease research and clinical programs.